Heart failure with a normal left ventricular ejection fraction: Epidemiology, pathophysiology, diagnosis and management

American Journal of the Medical Sciences

Volumn 346, Issue 2, 2013, Pages 129-136

  Garg, Nadish ^a   Senthilkumar, Annamalai ^a   Nusair, Maen B ^a   Goyal, Neha ^a   Garg, Rajeev K ^a   Alpert, Martin A ^a,b  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Diagnosis; Heart failure; Management; Normal left ventricular ejection fraction; Pathophysiology

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIGITALIS; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; NEBIVOLOL; PERINDOPRIL; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROPRANOLOL; RAMIPRIL; SILDENAFIL; SPIRONOLACTONE; VERAPAMIL;

ABLATION THERAPY; ARTERIAL STIFFNESS; ARTIFICIAL HEART PACEMAKER; DIABETES MELLITUS; DIASTOLIC HEART FAILURE; DOPPLER ECHOCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HEART MUSCLE REVASCULARIZATION; HEART VALVE REPLACEMENT; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROGNOSIS; REVIEW; SINUS RHYTHM; SODIUM INTAKE; SURVIVAL; TACHYCARDIA; UNITED STATES;

EID: 84880845107     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31828c586e     Document Type: Review

References (101)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guidelines update for the diagnosis and management of chronic heart failure. Circulation 2005;112:e154-235.
2. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391.
3. Bhatia RS, Tu JV, Lee DS. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355: 260-9.
4. Redfield MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.
5. Senni M, Redfield MM. Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol 2001;38:1277-82.
6. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998;98:2282.
7. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management. Ann Intern Med 1992;117:502-10.
8. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-27.
9. Aurigemma GP. Diastolic heart failure-a common and lethal condition by any name. N Engl J Med 2006;355:308-10.
10. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005;47:320-32.
11. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Eng J Med 2006;355:251-9
12. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999;33:1948-55.
13. Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol 2006;47:76-84.
14. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 2008;29:339-47.
15. Morgan S, Smith H, Simpson I, et al. Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. BMJ 1999;318:368-72.
16. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J 1999;20:447-55.
17. Dauterman KW, Go AS, Rowell R, et al. Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Cardiac Fail 2001;7:221-8.
18. Maurer MS, Burkhoff D, Fried LP, et al. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. J Am Coll Cardiol 2007;49:972-81.
19. McMurray JJ. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008;10:149-56.
20. Gustaffsson F, Torp-Pedersen C, Brendorp B, et al; for the DIAMOND study group. Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur Heart J 2003;24:863-70.
21. Fonarow GC, Stough WG, Abraham WT, et al; for the OPTIMIZEHF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768-77.
22. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009;53:1119-26.
23. Klapholz M, Maurer M, Lowe AM, et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol 2004;43:1432-8.
24. Melenovsky V, Borlaug BA, Rosen B, et al. Cardiovascular features of heart failure with preserved ejection fraction versus non-failing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 2007;49:198-207.
25. Hay I, Rich J, Ferber P, et al. Role of impaired myocardial relaxation in the production of elevated left ventricular filling pressure. Am J Physiol Heart Circ Physiol 2005;288:H1203-1208.
26. Westermann D, Kasner M, Steendijk P, et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008;117:2051-60.
27. Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001;104: 779-82.
28. Zile MR, Richardson K, Cowles MK, et al. Constitutive properties of adult mammalian cardiac muscle cells. Circulation 1998;98:567-79.
29. Borbely A, van der Velden J, Papp Z, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005;111:774-81.
30. Van Heerebeek L, Borbely A, Niessen HWM, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006;113:1966-73.
31. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation an passive stiffness of the left ventricle. N Engl J Med 2004;350:1953-9.
32. Kawaguchi M, Hay I, Fetics B, et al. Combined ventricular and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003:107:714-20.
33. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002;288:2144-50.
34. Maeder MT, Kay DM. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 2009;53:905-18.
35. Appleton CP, Kovais SJ. The role of left atrial function in diastolic heart failure. Circ Cardiovasc Imaging 2009;2:6-9.
36. Linke WA. Sense and stretch ability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. Cardiovasc Res 2008;77:637-48.
37. Villari B, Campbell SE, Hess OM, et al. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol 2009;22:1477-84.
38. Borlaug BA, Melenovsky V, Russell SD, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006;114:2138-47.
39. Zile MR, Adamson PB, Cho YK, et al. Hemodynamic factors associated with acute decompensated heart failure: part 1-insights into pathophysiology. J Card Fail 2011;17:282-91.
40. Witte KK, Nikitin NP, Cleland JG, et al. Excessive breathlessness in patients with diastolic heart failure. Heart 2006;92:1425-9.
41. Fung JWH, Sanderson JE, Yip GWK, et al. Impact of atrial fibrillation in heart failure with normal ejection fraction: a clinical and echocardiographic study. J Cardiac Fail 2007;13:649-55.
42. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985;312:277.
43. Carroll JD, Hess OM, Hirzel HO, et al. Left ventricular systolic and diastolic function in coronary artery disease: effects of revascularization on exercise-induced ischemia. Circulation 1985;72:119-29.
44. Eberli FR, Apstein CS, Ngoy S, et al. Exacerbation of left ventricular ischemic diastolic dysfunction by pressure-overload hypertrophy. Modification by specific inhibition of cardiac angiotensin converting enzyme. Circ Res 1992;70:931-43.
45. Poirer P, Bogaty P, Garneau C, et al. Diastolic dysfunction in normotensive men with well controlled type 2 diabetes. Diabetes Care 2001;24:5-10.
46. MacDonald MR, Petrie MC, Varyani F, et al; for the CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008;29:1377-85.
47. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease. J Am Coll Cardiol 2008;52:686-717.
48. Arias MA, Garcia-Rio F, Alonso-Fernandez A, et al. Obstructive sleep apnea syndrome affects left ventricular diastolic function: Effects on nasal continuous positive airway pressure in men. Circulation 2005; 112:375-83.
49. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-50.
50. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function Circulation 2002;105:1387.
51. Dickstein K, Cohen-Solal A, Filippatos F, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008;29:2388-442.
52. Paulus WJ, van Ballegorj JJM. Treatment of heart failure with normal ejection fraction. An inconvenient truth. J Am Coll Cardiol 2010; 55:526-37.
53. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101:2118-21.
54. Kasner M, Westermann D, Steendijk P, et al. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-cardiac catheterization study. Circulation 2007;116: 637-47.
55. Ommen SD, Nishimura RA, Appleton CP, et al. Clinical utility of doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler- catheterization study. Circulation 2000;102:1788-94.
56. Rossi A, Cicoira M, Florea VG, et al. Chronic heart failure with preserved left ventricular ejection fraction: diagnostic and prognostic value of left atrial size. Internat J Cardiol 2006;110:386-92.
57. Maisel AS, McCord J, Nowak RM, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003;41:2010-7.
58. Tschope C, Kasner M, Westermann D, et al. The role of the NTproBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005; 26:2277-84.
59. Kirk V, Bay M, Parner J, et al. N-terminal proBNP and mortality in hospitalized patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 2004;6:335-41.
60. Nielsen LS, Svaneguard J, Klitguard NA, et al. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnea. Eur J Heart Fail 2004;6:63-70.
61. Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiology and therapeutic implications. J Am Coll Cardiol 1993;22:318.
62. Michaelson A, Konig G, Thime W. Preventable precipitating factors leading to hospital admission with decompensated heart failure. Heart 1998:80:437-41.
63. Yip GWK, Wang M, Wang T, et al. The Hong Kong Diastolic Heart Failure study: a randomized controlled trial of diuretics, irbesartan and ramipril on quality of life capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008;94: 573-80.
64. Costanzo MR, Guglin ME, Saltzberg MT, et al; for the UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83.
65. Hung MJ, Cherng WJ, Kuo LT, et al. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Internat Clin Pract 2002;56:57-61.
66. Setaro JF, Zaret BL, Schulman DS, et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990;66:981-6.
67. Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short and long-term effects. Circulation 1985;72:853-64.
68. Alvares RF, Goodwin JF. Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. Br Heart J 1982;48:204-12.
69. Andersson B, Caidahl K, di Lenarda A, et al. Changes in early and late diastolic filling patterns induced by long-term adrenergic betablockade in patients with idiopathic dilated cardiomyopathy. Circulation 1996;94:673-82.
70. Dobre D, van Veldhuisen DJ, DeJogste MJL, et al. Prescription of beta-blockers in patients with advanced heart failure and preserved let ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail 2007;9:280-6.
71. Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004;6:453-61.
72. Nodari S, Metra M, Dei Cas L. b-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs nebivolol. Eur J Heart Fail 2003;5:621-7.
73. Van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53: 2150-8.
74. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on moratlity and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25.
75. Massie BM, Nelson JJ, Lakae MA, et al; for the COHERE Participant Physicians. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice. Am J Cardiol 2007;94: 1263-8.
76. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction $40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997;80: 207-9.
77. Hernandez AF, Hammill BG, O'Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009;53:184-92.
78. Ghio S, Magrini G, Serio A, et al; for the SENIORS investigators. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic sub-study. Eur Heart J 2006;27:562-8.
79. Cleland JGF, Tendera M, Adamus J, et al; on behalf of PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-45.
80. Cohn JN, Johnson G. Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group. Circulation 1990;81(suppl):III48-53.
81. Grigorian Shamagian L, Roman AV, Ramos PM, et al. Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study. J Cardiac Fail 2006;12:128-33.
82. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993;71:602-4.
83. Yusuf S, Pfeffer MA, Swedberg K, et al, Westergren J. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
84. Solomon SD, Anavekar N, Skali H, et al; for the Candesartan in Heart Failure Reduction in Mortality and Morbidity (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005;112: 3738-44.
85. McMurray JJ, Carson PE, Komaida M, et al; Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PERSERVE trial. Eur J Heart Fail 2008;10:149-56.
86. Massie BM, Carson PE, McMurray JJ, et al, Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359:2456-67.
87. Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004;110:558-65.
88. Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with and aldosterone antagonist trial: a randomized controlled spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011;162:966-72.
89. Edelman F, Schmidt AG, Gelbrich G, et al. Rationale and design of the aldosterone receptor blockade in diastolic heart failure trial: a double-blind, randomized, placebo-controlled paralleled group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur J Heart Fail 2010;12:874-82.
90. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin in morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006;114:397.
91. Jones RC, Francis GS, Lauer MS. Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group trial. J Am Coll Cardiol 2004;44:1025-9.
92. Guazzi M, Vicenzi M, Arena R, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011;12:164-74.
93. Fukuta H, Sane DC, Brucks S, et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005:112:357-63.
94. Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis dfor the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51:415-26.
95. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002;137:631.
96. Smith GL, Masoudi FA, Vaccarino V, et al. Outcomes in heart failure patients with dpreserved ejection-fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 2003;41:1510-8.
97. MacCarthy PA, Kearney MT, Nolan J, et al. Prognosis in heart failure with preserved left ventricular systolic function: prospective cohort study. BMJ 2003;327:78-9.
98. Zile MR, Gaasch WH, Anand IS, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010;121:1393-405.
99. Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J 2006; 151:444-50.
100. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a dbroad spectrum of patients with heart failure. Circulation 2006;113:671-8.
101. Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a novel prognostic dmarker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 2007;50:40-7.